Stay updated on MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety
Sign up to get notified when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.

Latest updates to the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page
- Check6 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.8%
- Check13 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant announcement regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference0.9%
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe expected modernization of the ClinicalTrials.gov data ingest has been postponed from June 2025 to July 2025, and the revision version has been updated from v2.16.2 to v2.16.4.SummaryDifference1.0%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check64 days agoChange DetectedThe page has removed a citation regarding the results of two phase 3 trials on Tildrakizumab for chronic plaque psoriasis, which may impact the credibility and comprehensiveness of the content related to this treatment.SummaryDifference0.2%
Stay in the know with updates to MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety
Enter your email address, and we'll notify you when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.